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ABSTRACT Functionalized gold nanoparticles with controlled geometrical and optical properties are the subject 
of intensive studies and biomedical applications, including genomics, biosensorics, immunoassays, clinical chem-
istry, laser phototherapy of cancer cells and tumors, the targeted delivery of drugs, DNA and antigens, optical 
bioimaging and the monitoring of cells and tissues with the use of state-of-the-art detection systems. This work 
will provide an overview of the recent advances and current challenges facing the biomedical application of gold 
nanoparticles of various sizes, shapes, and structures. The review is focused on the application of gold nanopar-
ticle conjugates in biomedical diagnostics and analytics, photothermal and photodynamic therapies, as a carrier 
for delivering target molecules, and on the immunological and toxicological properties. Keeping in mind the 
huge volume and high speed of the data update rate, 2/3 of our reference list (certainly restricted to 250 Refs.) 
includes publications encompassing the past 5 years.
KEYWORDS gold nanoparticles; plasmon resonance; biosensors; biomedical diagnostics; photothermal and pho-
todynamic therapy; targeted drug delivery; nanotoxicology
ABBREVIATIONS GNP – gold nanoparticles; PR – plasmon resonance; PPTT – plasmonic photothermal therapy; 
PEG – polyethylenglycol; SEM – scanning electron microscopy; TEM – transmission electron microscopy; PDT – 
photodynamic therapy; TNF – tumor necrosis factor; CTAB – cetyltrimethylammonium bromide; SPIA – sol 
particle immunoassay
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INTRODUCTION
Gold is one of the first metals to have been discovered; 
the history of its study and application spans at least 
several thousand years. The first data on colloidal gold 
can be found in treatises by Chinese, Arabian, and In-
dian scientists, who managed to obtain colloidal gold 
as early as in the V–IV centuries BC. They utilized it 
for medicinal purposes (Chinese “golden solution” and 
Indian “liquid gold”), amongst other uses. In Europe 
during the Middle Ages, colloidal gold was studied and 
used in alchemist laboratories. Paracelsus wrote about 
the therapeutic properties of gold quintessence — 
“quinta essentia auri,” which he obtained via the reduc-
tion of gold chloride by vegetable extracts in alcohols 
or oils. He used the “potable gold” for the treatment 
of a number of mental diseases and syphilis. His con-
temporary, Giovanni Andrea, used “aurum potabile” 
as a therapy for patients with leprosy, plague, epilepsy, 
and diarrhea. In 1583, the alchemist David de Planis-
Campy, who served as doctor to Louis XIII of France, 
recommended his “longevity elixir,” a colloidal solu-
tion of gold in water. The first book on colloidal gold 
preserved to our days  was published in 1618 by the 
philosopher and doctor of medicine Francisco Antonii 
[1]. It contains data on how to obtain colloidal gold and 
its application in medicine, including practical advice.
Copyright ©2011 Park­media, Ltd. This is an open access article distributed under the Creative
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Despite its centuries-old history, the “revolution in 
immunochemistry” associated with the use of gold na-
noparticles (GNP) in biological studies occurred only in 
1971, when the British researchers Faulk and Taylor 
[2] described a method of antibody conjugation with 
colloidal gold for direct electron microscopy visualiza-
tion of the surface antigens of salmonellae. The study 
was initiated using biospecific markers – colloidal gold 
conjugated with immunoglobulins and other molecules 
– in different spheres of biology and medicine. Over the 
past 40 years, there have been many studies devoted to 
the application of functionalized nanoparticles – con-
jugates with recognizing biomacromolecules (antibod-
ies, lectins, enzymes, aptamers, etc.) – in biochemistry, 
microbiology, immunology, cytology, plant physiology, 
morphology, etc.
The range of GNP use in modern medical and biol-
ogy studies is extremely wide. In particular, it com-
prises genomics, biosensorics, immunoanalysis, clinical 
chemistry, detection and photothermolysis of micro-
organisms and cancer cells; the targeted delivery of 
drugs, DNA and antigens; optical bioimaging and the 
monitoring of cells and tissues using modern registra-
tion systems. It has been argued that gold nanoparticles 
could be used in almost all medical applications: diag-
nostics, therapy, prevention, and hygiene. A wealth of 
information on how to obtain and use colloidal gold in 
biology and medicine, as well as how it functions, can 
be found in books and reviews [3–8]. The broad range 
of applications for GNP is based on their unique physi-
cal and chemical properties. In particular, the optical 
properties of GNP are determined by their plasmon 
resonance, which is associated with the collective exci-
tation of conduction electrons and localized in the broad 
region, from the visible to the infrared (IR) region, de-
pending on the particle size, shape, and structure [9].
Taking into account the large volume of data pub-
lished and the high speed at which they are updated, 
our review aimed to generalize the results obtained 
over the past several years in the most promising di-
rections in the use of GNP in modern medical and bio-
logical studies.
1. GOLD NANOPARTICLES IN DIAGNOSTICS
1.1. Visualization and bioimaging 
Gold nanoparticles have been in active use in the iden-
tification of chemical and biological agents. Electron 
microscopy (predominantly, transmission electron mi-
croscopy — TEM) has historically remained the pre-
dominant means to detect biospecific interactions using 
colloidal gold particles (due to their high electron den-
sity). It is not by happenstance that the first three-vol-
ume publication about the application of colloidal gold 
[10] was chiefly devoted to TEM using GMP. The use 
of high-resolution instruments (high-resolution trans-
mission electron microscope – HRTEM) and systems of 
digital recording and the processing of images are ex-
amples of the modern application of electron microsco-
py equipment. The main practical use of immune elec-
tron spectroscopy in modern medico-biological studies 
is for the identification of causative agents of infectious 
diseases and their surface antigens [11] (Fig. 1A). Scan-
ning probe microscopy [12] (Fig. 1B), scanning electron 
microscopy [13], and fluorescence microscopy [14] are 
frequently used for the same purpose.
In addition to the conventional colloidal gold with 
quasi-spherical particles (nanospheres), non-spherical   
particles, such as nanorods, nanoshells, nanocages, na-
nostars, and other types of particles (this group of par-
ticle were named “plasmon resonance particles of noble 
metals”) have recently been used [8] (Fig. 2).
The visualization methods with the use of GNP and 
optical microscopy [27], in particular, confocal laser mi-
croscopy, have gained increasing popularity in medical 
and biological research. Confocal microscopy is a meth-
od for the detection of micro-objects using an optical 
system, which permits the registering of light radiation 
only from the objects located in its focal plane; there-
fore, the scanning of samples along their height can be 
performed, and their 3D images can be obtained by su-
perposition of scanograms. The use of GNP and anti-
body–GNP conjugates allows for real-time detection 
of the penetration of gold into living cells (e.g., cancer 
cells) at the level of a single particle and even for the 
estimation of their amount [28].
The methods for obtaining confocal images include 
fluorescence detection (confocal fluorescence micros-
copy) or resonance elastic or two-photon (multiphoton) 
light scattering by plasmon nanoparticles (resonance 
scattering confocal microscopy or two-photon lumines-
a 0.5 µm b 0.5 µm
Fig. 1. TEM image of a Listeria monocytogenes cell (a) 
and AFM image of a tobacco mosaic virus labeled by col-
loidal gold nanoparticles conjugated with the correspond-
ing antibodies. (b). Adapted from Refs. [11] (а) and [12] 
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cence confocal microscopy). These techniques are based 
on detecting micro-objects using an optical microscope 
in which the object’s luminescence is excited due to the 
simultaneous absorption of two (or more) photons; the 
energy of each of them being lower than that required 
for fluorescence excitation. The major advantage of 
this method is that the strong decrease in the back-
ground signal results in the contrast being enhanced. 
The use of two-photon luminescence of gold nanopar-
ticles allows to visualize (amongst other objects) on-
comarkers on the surface or inside a cell [29, 30]. Fig-
ure 3A provides an example of combined bioimaging 
of a malignant cell using adsorption, fluorescence, and 
luminescence plasmon resonance labels.
Dark-field microscopy based on light scattering by 
microscopic objects (resonance scattering dark-field 
microscopy), including objects with a size less than the 
resolution limit of a light microscope, remains one of 
the most popular methods in bio-imaging using GNP 
(Figs. 3B, C). Upon dark-field microscopy, only the light 
scattered by an object under lateral illumination can 
reach the lens (similar to the Tyndall effect); therefore, 
the scattering object shines brightly against the dark 
background. Gold nanoparticles offer more possibili-
ties for the detection of biospecific interactions using 
dark-field spectroscopy in comparison with fluores-
cence labels [8], since the scattering cross-section of a 
particle is higher than the fluorescence cross-section 
of one molecule by 3–5 orders of magnitude. This prin-
ciple was applied by American researchers at the El-
Sayed laboratory [31] in a new method for a simple and 
reliable diagnostics of oncologic diseases with the use of 
GNP. The method is based on the preferential binding 
of GNPs conjugated with antibodies specific to tumor 
antigens to the surface of cancerous cells, as compared 
with binding to healthy cells. Thus, resonance scatter-
ing dark-field microscopy can be used to map a tumor 
with an accuracy of up to several cells (Figs. 3B, C). In 
subsequent studies, gold nanorods [32], nanoshells [33], 
nanostars [34], and nanocages [35] were used with the 
same purpose.
Nanocages belong to a relatively new family of na-
noparticles fabricated by galvanic replacement on sil-
ver nanocube templates. In this reaction, three silver 
atoms are replaced by a single gold atom, resulting in 
the gradual formation of various porous alloy struc-
tures of gold and silver, which are called nanoboxes and 
nanocages [35]. In the formation process of these parti-
cles, the plasmon resonance shifts from 430–440 nm for 
cubes to 700–900 nm for nanocages.
The use of nonspherical and/or heterogeneous par-
ticles, as well as self-assembling particle monolayers 
a  b  c  d
e  f  g  h
i  j  k  l
100 nm 100 nm 50 nm 25  nm
200 nm 500 nm 500 nm 200 nm 100 nm
100 nm 100 nm 250 nm
100 nm 50 nm
Fig. 2. Various types of gold plas-
mon-resonance nanoparticles: 16-nm 
nanospheres (a) [8], nanorods (b) 
[15], bipyramids (с) [16], gold nano-
rods with silver coating (d) [17], “na-
norice” – Fe2O3 nanorods covered 
by a gold nanoshell (e) [18], gold 
nanoshells onto silica cores, SiO2/
Au (f) [19] (the inset shows a hol-
low gold nanoshell [20]), nanobowls 
with a gold seed on the bottom (g) 
[21],“spiky nanoshells” with SiO2/Au 
cores [22] (the inset shows a “nanos-
tar” particle [23]) (h), tetrahedra, oc-
tahedra, and cubooctahedra (i) [24], 
nanocubes (j) [24], silver nanocubes 
and gold-silver nanocages obtained 
with silver cube templates (insets) 
(k) [25], nanonecklaces [26] (l). The 
figures were adapted from the cited 
works. The figures are reproduced 
by permission from The Royal Soci-
ety of Chemistry (http://dx.doi.
org/10.1039/b711490g, http://
dx.doi.org/10.1039/c0cs00018c), 
The PCCP Owner Societies (http://
dx.doi.org/10.1039/b925102b) and 
The American Chemical Society.REVIEWS
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or island films, opens up new opportunities to enhance 
sensitivity in detecting biomolecular binding on or near 
the surface of nanostructures. The principle of amplifi-
cation of the biomolecular binding signal is based on in-
ducing strong local electromagnetic fields near particles 
with sharp regions on their surface or in the narrow (on 
the order of nanometer or less) gaps between two na-
noparticles. It stipulates enhanced sensitivity of plas-
mon resonance to the local dielectric environment and 
a high scattering intensity in comparison with spheres 
of the same volume. Therefore, these nanostructures 
can be considered as having significant potential for 
application for biomedical diagnostics purposes using 
dark-field microscopy [36].
Gold nanoparticles are used in resonance scatter-
ing dark-field microscopy for the detection of micro-
bial cells and their metabolites [37], the bio-imaging of 
tumor cells [38], and for the detection of receptors on 
their surface [39], and for the study of endocytosis [40]. 
In most biomedical applications, the efficacy of label-
ling cells with conjugates is assessed at the qualitative 
level. The method of quantitative assessment of the ef-
ficacy of cell labelling with gold nanoparticles that was 
used for labelling pig embryo kidney cells with gold 
nanoshell conjugates is one of the few exceptions [41].
In addition to the aforementioned methods used to 
detect biospecific interactions using different variants 
of optical microscopy and GNP, other modern methods 
for detecting and bio-imaging have recently been in 
active development; these methods can be combined 
under the general name “biophotonic methods” [9]. Bio-
photonics combines all studies associated with the in-
teraction between light and biological cells and tissues. 
Biophotonic methods include optical coherence tomog-
raphy [42], X-ray and magneto-resonance tomography 
[43, 44], photoacoustic microscopy [45] and tomography 
[46], fluorescence correlation microscopy [47], etc. Gold 
nanoparticles of various sizes and shapes are also suc-
cessfully used in these methods. We believe that bio-
photonic methods with the use of gold non-spherical 
nanoparticles may prove to be of considerable promise 
for in vivo bioimaging [48]. Moreover, the significance 
of a new class of GNP conjugates with recognized con-
structions based on the barnase–barstar module [49] 
should be noted.
 
1.2. Analytic methods for diagnostics
1.2.1. Homophase methods. Beginning in the 1980s, con-
jugates of colloidal gold and recognizing biomacromol-
ecules began to be used in various analytic methods of 
clinical diagnostics. In 1980, J. Leuvering et al. [50] pro-
posed a new method that was called sol particle immu-
noassay (SPIA). This method is based on two principles: 
1) the color and absorption spectrum of a sol vary little 
upon biopolymer adsorption on individual particles [51]; 
2) when particles approach a distance that is less than 
one-tenth of their diameter, the sol’s red color changes 
into purpuric; the absorption spectrum broadens and 
shifts into the red region [51]. These changes in the ab-
sorption spectrum can be easily detected either spec-
trophotometrically or visually (Fig. 4, [52]).
An optimized version of this method (using larger 
gold particles and monoclonal antibodies to various 
sites of an antigen) was applied to detect chorionic gon-
adotropin in the urine of pregnant women [53]. On the 
basis of these elaborations, Chefaro Company (Neth-
erlands) launched the Discretest™ kit for early out-of-
hospital diagnosis of pregnancy. Kits for immune col-
a  b  c
Fig. 3. a - Confocal image of HeLa cells in the presence of gold nanoparticles. The nucleus was stained with a Hoechst 
33258 reagent (in blue), whereas the actin cytosceleton was stained with an Alexa Fluor 488 labeled falloidine (in red), 
and gold nanoparticles (in green) were detected by two-photon luminescence [30]. A dark-field microscopic image 
of cancer (b) and healthy (c) cells with gold nanoparticles conjugated with antibodies to EGRF [31]. Adapted from the 
cited works by permission from The American Chemical Society. 38 | ACTA NATURAE |  VOL. 3  № 2 (9)  2011
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orimetric determination of the rheumatoid factor and 
streptolysin are produced by PLIVA Lachema Com-
pany (Czech Republic).
This method was subsequently used for performing 
immunoassay of the antigens of schistosomes and ru-
bella viruses and for the quantitative determination of 
immunoglobulins (refs. in [5]), for determining thrombin 
(using aptamers) [54] and glucose [55], for the direct de-
tection of cancer cells [56] and leptospira cells in urine 
[57], and for determining markers of Alzheimer’s disease 
[58] and protease activity [59]. The simultaneous use of 
conjugates of gold nanorods and nanospheres with an-
tibodies for detecting tumor antigens was described in 
[60]. The data on the determination of the hepatitis B vi-
rus in blood using gold nanorods conjugated with spe-
cific antibodies were published in [61].
The implementation of all versions of the SPA meth-
od proved to be relatively simple but at the same time 
both highly sensitive and specific. However, in a num-
ber of cases, despite the evident complementarity of 
a pair, no aggregation took place; the solution’s color 
and the absorption spectra either did not change or 
changed to an insignificant degree. The model of for-
mation of the second protein layer on gold particles 
without a loss in the aggregate stability of the sol was 
suggested in [62]. The changes in spectra caused by ad-
sorption of biopolymers on the surface of gold nano-
particles are relatively small. However, even such neg-
ligible changes in absorption spectra resulting from the 
change in the biopolymer layer structure  (or, equiva-
lently, in its average refractive index) near the GNP 
surface can be recorded and used for a quantitative 
analysis in biological applications [63]. 
Various optical methods, including different versions 
of IR Fourier [64] and UV-vis beam absorption or de-
flection spectroscopy (see refs. in [5]), hyper-Rayleigh 
[65], differential static [51], and dynamic [60] light scat-
tering, as well as surface-enhanced Raman scattering 
[66], have been used to enhance the sensitivity of the 
analytical homophase reaction.
A new version of the SPIA method was proposed 
by C. Mirkin et al. [67] for the colorimetric detection 
of DNA. Currently, the colorimetric determination of 
DNA involves two strategies: (1) the use of GNP con-
jugated with thiol-modified single-stranded DNA [67–
71] and (2) the use of nonmodified GNP [72, 73]. The 
first strategy is based on the aggregation of conjugates 
of 10–30 nm GNP with thiol-modified single-stranded 
DNA probes upon introduction of target polynucleo-
tides into the system. In this case, probes of two types 
are used, which are complementary to two terminal re-
gions of the targets. Hybridization of targets and probes 
results in the formation of GNP aggregates, which is 
accompanied by changes in the absorption spectrum of 
the solution and can be easily detected visually, pho-
tometrically [74], or via dynamic-light scattering [71]. 
Within the framework of the first strategy proposed by 
Maeda et al. [75], the diagnostic system based on the ag-
gregation of GNP modified by probes of one type upon 
introduction of DNA targets into the solution under 
conditions of high ionic strength was used. Meanwhile, 
Baptista et al. [70] elaborated a method based on the 
enhanced stability of conjugates upon the introduction 
of complementary targets even under conditions of 
high ionic strength (2 M NaCl), and the aggregation of 
noncomplementary targets was observed. The appar-
ent contradictions between the two approaches were 
ascribed [76] to the difference in the surface function-
alization density. 
The second strategy [72] is based on the fact that the 
single-stranded DNA protects unmodified GNP against 
aggregation upon high ionic strength, while the forma-
tion of duplexes upon hybridization cannot stabilize the 
system. This approach was used to determine the hepa-
titis C virus [77]. Xia et al. [78] recently described a new 
variant of the second strategy in which single-stranded 
DNA, unmodified GNP, and cationic polyelectrolyte 
are used. The same approach turned out to be suit -
able for determining a wide range of targets, includ-
ing peptides, amino acids, pesticides, antibiotics, and 
heavy metals. Contrary to the procedures with usual 
GNP, He et al. [73] proposed a method for determining 
HIV-1 U5 viral DNA using nanorods stabilized by ce-
tyltrimethylammonium bromide (CTAB) and the light 
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Fig. 4. Sol-particle immunoassay: 
a scheme of conjugate aggrega-
tion caused by binding to target 
molecules (a) and corresponding 
changes in the sol color and absorp-
tion spectra (b). Adapted from Ref. 
[52] by permission from The Ameri-
can Chemical Society.REVIEWS
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scattering method with a detection limit of about 100 
pM. In the optimized version where absorption spec-
troscopy is used [79], the detection limit was reduced 
to 0.1 pM. It has been recently demonstrated that posi-
tively charged GNP coated with CTAB can be used for 
the detection of DNA targets in combination with spec-
troscopy and dynamic scattering methods [15].
The enumerated versions of the method of sol parti-
cle aggregation due to the hybridization reaction were 
used to determine the DNA of micobacteria [70], staph-
ylococci [80], streptococci [81], and chlamydiae [82] in 
clinical samples.
The ability of gold particles to aggregate upon in-
teraction with proteins inducing colour change in the 
solution served as the basis for the quantitative method 
of colorimetric determination of proteins [83]. A new 
version of the SPIA method using microtitration plates, 
an ELISA reader, and colloidal gold-trypsin conjugates 
was proposed for the detection of proteins [84].
1.2.2. Dot immunoassay. At the early stages of the de-
velopment of immunoassays, preference was given to 
liquid phase techniques, in which the bound antibodies 
were deposited or the unbound antigen was removed 
using dextran-coated activated coal. The solid-phase 
techniques have recently been the most widely used 
(first used in radioimmunoassay of proteins), since they 
provide the possibility to considerably simplify the 
analysis procedure and reduce the background signal. 
The most widespread solid-phase carriers are poly-
styrene plates and nitrocellulose membranes.
Radioactive isotopes (125I, 14C, 3H) and enzymes (per-
oxidase, alkaline phosphatase, etc.) are widely used as a 
label in membrane tests (dot and blot analyses). In 1984, 
four studies were independently published [85–88] in 
which colloidal gold was used as a label for solid-phase 
immunoanalysis. The use of GNP conjugates in solid-
phase analysis is based on the fact that the intense red 
coloration of a gold-containing marker allows one to de-
termine visually the results of a reaction that was car-
ried out on a solid carrier. “Immuno-gold techniques” in 
dot blot assay are superior to the other types of assays 
(e.g., immunoenzyme assay) in sensitivity (Table 1, [89]), 
simplicity, speed, and cost. The GNP size after the cor-
responding immunochemical reaction can be increased 
using the reaction of amplification with silver [90] or 
gold salts (autometallography) [91], which considerably 
broadens the limits of application of this method. The 
optimized version of solid-phase assay using the Quan-
tity One densitometry system (Bio-Rad, USA) provided 
a linear range of detection from 1 pM to 1 µM [92] with 
a limit of 100 aM and its decrease to 100 zM by silver 
amplification. It should be kept in mind that this record 
decrease in the detection limit due to silver amplifica-
tion was attained using the sensitive densitometry sys-
tem (Quantity One). The modern instrument methods, 
such as photothermal deflection of a probe laser beam 
induced by heating of the local environment near the 
absorbing particles by heating laser pulses (LISNA 
[93]), also ensure a very broad detection range: from 
several orders of magnitude to several isolated particles 
per blot.
When carrying out specific staining, the membrane 
with the material applied on it is incubated in a solu-
tion containing antibodies (or other biospecific probes) 
labelled with colloidal gold [94]. Immunoglobulins, Fab- 
and scFv- antibody fragments, protein A, lectins, en-
zymes, avidin or anti-biotin antibodies upon the study 
of biotin conjugated samples, aptamers, and other 
recognizing molecules are used as probes when car-
rying out “gold” dot or blot assay. Several labels can 
be simultaneously used as well (e.g., colloidal gold and 
peroxidase or alkaline phosphatase) to reveal different 
antigens on a membrane.
Colloidal gold in membrane tests was used to diag-
nose parasitic, virus, and fungus diseases; tuberculosis, 
melioidosis, syphilis, brucellosis, shigellosis, and coli-
infections; to determine blood groups and pregnancy 
at an early stage, for dot blot hybridization, and for re-
vealing the diphtheritic toxin, diagnostics of myocar-
dial infarction, and hepatitis B (see refs. in [5]).
Immunodot assay is one of the simplest methods for 
determining the antigens immobilized on membranes; 
in some cases, this method allows one to estimate their 
quantitative content. Most frequently, immunodot as-
say is used to study soluble antigens [95]. However, few 
studies have been published in which corpuscular an-
tigens (whole bacterial cells) were studied by dot assay 
with enzyme labels [96]. The procedure of dot assay in 
whole bacterial cells with visualization of the reaction 
products using colloidal gold conjugates as biospecific 
markers (“cell-gold immunoblotting”) was first used 
for serotyping soil nitrogen-fixating microorganisms 
of the Azospirillum genus [97]. This method was sub-
Table 1. The sensitivity limits of the immunodot/blot 
methods on nitrocellulose filters using various labels (ac-
cording to [89])
Label Sensitivity limit, pg 
of protein/fraction
125I 5
Horseradish peroxidase 10
Alkaline phosphatase 1
Colloidal gold 1
Colloidal gold + silver 0.1
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sequently used for express diagnostics of enteric infec-
tions [98].
The results of applying gold nanoshells as biospecific 
labels for dot assay were first presented in paper [99], 
where three types of gold nanoshells with diameters 
of the silicate nucleus of 100, 140, and 180 nm and gold 
shell thickness of approximately 15 nm were studied. 
Normal rabbit serum (target molecules) and sheep 
anti-rabbit immunoglobulins (recognizing molecules) 
were used as a biospecific pair. When using the stand-
ard protocol of the dot assay on a nitrocellulose mem-
brane with 15-nm colloidal gold nanoparticles as labels, 
the minimum detectable amount of rabbit IgG was 
equal to 15 ng. The replacement of the colloidal gold 
conjugates for nanoshells enhanced the assay sensitiv-
ity to 0.2 ng in the case of gold nanoshells of 180/15 nm, 
and to 0.4 ng in the case of gold nanoparticles of 100/15 
and 140/15 nm type (Fig. 5). Such a noticeable increase 
in the sensitivity of the dot assay with nanoshells, in 
comparison with colloidal gold, was explained by the 
differing optical properties of the particles [100].
The use of GNP seems to have a high potential for 
analyzing large arrays of antigens in micromatrices 
(immunochips) [101], which permits the simultaneous 
determination of the analyzed compound in 384 sam-
ples at a concentration of 60–70 ng/l or (taking into 
account the microliter amounts of the sample and the 
immunogold marker) with a detection limit of less than 
1 pg.
1.2.3. Immunochromatography. Approximately 10 
years ago, several foreign companies launched immu-
nochromatographic test systems for instrument-free 
diagnostics. Due to the high specificity and sensitivity 
of the immunoassay, these tests found wide applica-
tion in determining narcotic agents, toxins, early diag-
nostics of pregnancy, and screening of extremely dan-
gerous and urogenital infections. New methods for the 
diagnostics of tuberculosis, helicobacteriosis, staphy-
lococcus infection, hepatitis B, prostatitis, determin-
ing pregnancy at the early stages, pesticides, aflatoxin, 
diethylstilbestrol and cephalexin in the environment, 
and DNA hybridization have been elaborated (see refs. 
in [5]). 
Immunochromatographic assay [102] is based on elu-
ent motion along the membrane (lateral diffusion), re-
sulting in the formation of specific immune complexes 
that are detected as stained bands on different mem-
brane regions. Enzymes, stained latexes, and quantum 
dots [102] are used as labels in these systems; however, 
in the overwhelming majority of cases, gold nanoparti-
cles are used [103].
The sample under investigation migrates along the 
test strip due to capillary forces. If a sample contains 
the desired compound or immunologically close ones 
when the sample passes through the absorbing device, 
a reaction with specific antibodies labelled with colloi-
dal gold occurs, accompanied by the formation of an 
antigen–antibody complex. The colloidal preparation 
is involved in the reaction of competitive binding with 
the antigen immobilized in the test zone (haptene con-
jugated with a protein carrier is usually used for im-
mobilization in the detection of low-molecular-weight 
compounds). If the concentration of antigens in the 
sample is higher than the threshold level, the conjugate 
has no vacant valences for interacting in the test zone; 
the stained band corresponding to complex formation 
is not observed. If the sample does not contain the de-
sired compound, or its concentration is lower than the 
threshold level, antigen immobilized in the test zone of 
the strip reacts with antibodies on the surface of col-
loidal gold, which results in the formation of a stained 
band.
As the liquid front moves further, gold particles with 
immobilized antibodies, which did not react with the 
antigen in the test zone of the strip, are bound to an-
tispecific antibodies in the control zone of the test strip. 
The emergence of a stained band in the control zone at-
tests to the validity of the testing procedure and the di-
agnostic activity of the components of the system. The 
negative testing result, the emergence of two stained 
bands (in the test zone and the control zone), points 
to the fact that the sample contains no antigen or its 
Au-15 nm
SiO2/Au-180/15 нм
twofold dilutions
1
1
2
1
1
2
Fig. 5. Dot immunoassays of a normal rabbit serum (1) by 
using 15-nm GNPs and silica/gold nanoshells (180-nm-
core diameter and 15-nm gold shell) conjugated to 
sheep’s antirabbit antibodies. The IgG quantity equals 
1 µg for the first (upper left) square and is decreased by 
twofold dilution (left to right). The bottom rows (2) cor-
respond to a negative control (10 µg BSA in each square). 
Adapted from Ref. [100].REVIEWS
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concentration is lower in comparison with the thresh-
old level. The positive testing result, the emergence 
of a single stained band in the control zone attests to 
the fact that antigen concentration is higher than the 
threshold concentration (Fig. 6).
The study of these test systems has demonstrated 
their high stability, the reproducibility of the results, 
and correlation with alternative methods. Densitomet-
ric characterization of the degree of heterogeneity of 
the samples stands at 5–8%, which enables one to visu-
ally assess the results of the analysis with an appreci-
ably reliable accuracy. These tests are very simple and 
convenient to use.
1.2.4. Plasmon resonance biosensors. Over the past 
years, gold and silver nanoparticles and their compos-
ites have found broad application as efficient optical 
detectors of biospecific interactions [104]. In particular, 
the resonance optical properties of nanometer-sized 
metal particles have found successful application in the 
design of so-called biochips and biosensors. There are 
many types of sensors, viz. colorimetric, refractometric, 
electrochemical, piezoelectric, and certain others [102, 
105, 106]. These devices are of great interest in biology 
(determination of nucleic acids, proteins, and metabo-
lites); medicine (drug screening, analysis of antibodies 
and antigens, diagnostics of infectious diseases); and 
chemistry (environmental express monitoring, quanti-
tative analysis of solutions and dispersed systems).
The study of the biospecific interactions in such 
systems, where GNP are represented by ordered 
structures (self-assembling thin films) [107] or within 
polymer matrices [108], has been developing for over 
a decade. In this case, the amplification of the opti-
cal signal from the conjugate due to the strengthen-
ing of the exciting local field in an aggregate that was 
formed from gold nanoclusters is used. New unique 
technologies are currently being used for the design of 
biosensor devices, including monolayer self-assembly 
of metal particles (see [109] and refs therein), nano-
lithography [110], vacuum evaporation [111], etc. It is 
of fundamental significance to note that particle size 
and shape [112], interparticle distance [113], and the 
optical properties of the local environment [114] have 
a considerable effect on the optical response obtained 
from nanoparticles or their aggregates (in particular, 
the ordered ones), which provides the possibility of 
controlling the sensor’s “tuning.” These properties of 
metal clusters served as the basis for the design of new 
promising plasmon resonance biosensor systems (SPR-
biosensors) based on the conversion of biospecific in-
teractions into an optical signal. The theory behind the 
designing process and variants of practical application 
of such systems were considered in reviews [115–119].
Sensor sensitivity, stability, and selectivity directly 
depend on the characteristics of the optical registra-
tion system. BIAcore™ is the most popular sensor sys-
tem of this kind [120]. The measurement principle in 
planar, prismatic, or mirror biosensors is analogous to 
the principle used in the method of frustrated total in-
ternal reflection, which has been conventionally used 
to measure the thickness and the refractive index of 
ultrathin organic films on metal (reflecting) surfaces 
[105]. Plasmon resonance excitation in a planar gold 
layer occurs when polarized light falls onto the surface 
at a certain angle. The electromagnetic fields running 
along the boundary of the surface and localized in its 
proximity due to the exponential decrease in the am-
plitude perpendicular to the dielectric with a typical 
attenuation distance of up to 200 nm are excited on the 
metal/dielectric interface (the effect of total internal 
reflection, Fig. 7). The index of refraction at a certain 
angle and at a certain wavelength depends on the di-
electric properties of the thin layer on the interface, 
which are determined in the final analysis by the con-
centration of target molecules in the layer.
Various types of biosensors using GNP have been 
developed for immunodiagnostics of tick-borne en-
cephalitis [121], human papilloma [122] and immuno-
1 2
Fig. 6. Positive (1) and negative (2) results of an immuno-
chromatographyc assay.
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Fig. 7. Scheme 
for detection of 
target molecules 
with a BIAcore™ 
device based on 
a total internal 
reflection prism 
covered by a 
thin gold layer. 
Adapted from 
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deficiency-associated [123] viruses, Alzheimer’s disease 
[124], the determination of phosphororganic com -
pounds and pesticides [125], antibiotics [126], allergens 
[127], cytokines [128], hydrocarbons [129], immuno-
globulins [130], for detecting tumor [131] and bacterial 
[132] cells, and for determining the activity of cerebral 
cells [133].
GNP-based biosensors are applied not only in immu-
noanalysis [134], but also for the detection of nucleotide 
sequences [67, 119]. A record sensitivity was achieved 
for these sensors in pioneer studies [135, 136] in the 
zepto-molar range based on the recording spectra of 
resonant scattering from individual particles. This 
opened the door for the registration of intermolecular 
interactions at the level of individual molecules [137].
2. GOLD NANOPARTICLES IN THERAPY
2.1. Photothermal therapy using gold nanoparticles
Photothermal cell damage is a promising direction in 
both tumor therapy [138] and the therapy of infectious 
diseases, which has been intensively developing. The 
essence of this technique is as follows: gold nanopar-
ticles reach their absorption maximum in the visible 
or near-infrared region and become hot when irradi-
ated at the corresponding light wavelength. If they are 
located inside or around the target cells (which can be 
achieved by conjugation of gold particles with antibod-
ies or other molecules), these cells die.
Thermal exposure has been used in tumor therapy 
since the 18th century. To do that, both local heating 
(using microwave, ultrasound, and radio radiation) and 
hyperthermia of the entire organism [139] (heating to 
41–47°С for 1 h) [139] were applied. Upon local heating 
to 70°С, the duration of the procedure can be reduced 
to 3–4 min. Local and general hyperthermia result in 
irreversible cell damage caused by the disruption of the 
cell’s membrane permeability and protein denatura-
tion. Healthy tissues are also clearly damaged in this 
process. All this imposes considerable restrictions on 
the application of this method.
The revolution in cancer thermotherapy was trig-
gered by the use of laser radiation, which made con-
trolled and directed damaging of tumor tissues possible 
[140]. The combination of laser radiation with fiber-op-
tic waveguides gave excellent results and was named 
interstitial laser hyperthermia [141]. The disadvantages 
of laser therapy include the low selectivity associated 
with the necessity of using powerful lasers for the ef-
ficient stimulation of tumor cell death.
In 2003, GNP were applied for the first time as 
agents for photothermal therapy [142, 143]; it was lat-
ter proposed to refer to this kind of therapy as plas-
monic photothermal therapy (PPTT) [139]. A new 
method for selective damaging of target cells, which is 
based on the use of 20–30 nm gold nanospheres radi-
ated by 20 ns laser pulses (532 nm) in order to create lo-
Tumor
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Fig. 8. Scheme (left) and photothermal therapy of tumor-burdened mice (2-3 weeks after injection of MDA-MB-435 
human cancer cells into opposite flanks). Laser irradiation (a, b, 810 nm, 2 Wt/cm2, 5 min) were performed 72 h after 
injection of PEG-coated gold nanorods (NR) (a, с, 20 mg Au/kg) or saline buffer (b, d). It can be seen that the irradia-
tion without particles (control b), as well as the injection of nanorods or saline without irradiation (controls c and d), had 
no destructive effect, whereas the nanoparticle and laser treatment completely destroyed tumor. Adapted from Ref. 
[145] by permission of the Publisher.REVIEWS
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cal warming-up, was described in [144]. The sandwich 
technology consisting in labeling T-lymphocytes with 
GNP conjugates was used for the pulse photothermy 
in the model experiment. The use of GNP for the pho-
tothermal therapy of chemotherapy-resistant types of 
cancers seems to be the most promising direction. As 
opposed to photosensitizers (see below), GNP appear 
unique because the cells retain their optical properties 
under certain conditions for a significant amount of 
time. Successive irradiations with several laser pulses 
allows to control cell inactivation using a method that is 
not traumatic, while the use of the nanoparticles, prop-
erties to simultaneously scatter and absorb radiation 
makes PPTT possible using optical tomography [33].
Figure 8 represents an example of the successful 
therapy of induced tumors in mice [145]. Further devel-
opment of PPTT and its introduction in clinical prac-
tice will depend on how successful scientists will be in 
solving a host of problems,  the most significant ones 
being 1) selecting nanoparticles with the optimal optic 
properties; 2) increasing the contrast of nanoparticle 
accumulation in a tumor and decreasing overall poten-
tial toxicity; and 3) elaborating methods for delivering 
optical radiation to the targets and searching for alter-
native irradiation sources, which would combine high 
permeation ability with the possibility of GNP heating.
The first requirement is determined by the coinci-
dence of the spectral position of the maximum of the 
plasmon absorption resonance and the biotissue trans-
parency window in the near-infrared region (700–
900 nm). The summarizing theoretical analysis of the 
photothermal efficiency of GNP depending on their 
size, shape, structure, and degree of aggregation has 
been published [113]. It was shown that although gold 
nanospheres are inefficient in the near-infrared range, 
their aggregates can be very efficient at appreciably 
small interatomic distances (below 10% of their diam-
eter). Such clusters form both on a cell’s surface and 
inside cells [146]. Data on the amplification of PPTT due 
to clusterization were obtained [147, 148]. In particular, 
it was ascertained [147] that small aggregates consist-
ing of 30 nm particles enable the destruction of cancer 
cells at an intensity lower than that in the particle-free 
control by a factor of 20.
The parameters of gold nanoshells and nanorods that 
are optimal for PPTT were determined [113, 149]. To-
day, a number of studies have been published in which 
the application of gold nanorods [32, 150], nanoshells 
[142, 151], and a relatively new class of particles – gold-
silver nanocages [152, 153] – for PPTT is described. The 
results of a comparison of the efficiency of heating na-
norods, nanoshells, and nanocages are provided in [25, 
154].
Three fundamental things should be kept in mind in 
connection with the optimization of the parameters of 
a particle. First, intrinsic absorption is not the only pa-
rameter determining the efficiency of PPTT [155]. The 
rapid heating of nanoparticles or clusters results in the 
formation of vapor bubbles [156], which can cause cavi-
tation cell damage upon irradiation with visible [148] or 
near-infrared light [157]. The efficiency in the forma-
tion of vapor bubbles considerably improves upon the 
formation of nanoparticle clusters [143, 146]. It is possi-
ble that it is this effect, instead of the enhanced absorp-
tion, that determines the larger extent of cell damage, 
other conditions being equal [155]. Finally, irradiation 
of nanoparticles by high-intensity resonance nanosec-
ond IR pulses may result in the destruction of particles 
as early as after the first pulse (e.g., see [158, 159] and 
refs. therein). In a series of studies, Lapotko et al. (see 
[160] and refs. therein) focussed their attention on the 
fact that the heating of GNP and their destruction may 
result in an abrupt decrease in the photothermal effi-
cacy of “cold” particles tuned to the laser wavelength. 
The use of femtosecond pulses does not solve this prob-
lem because of the low energy supplied; therefore, it is 
necessary to accurately control the retention of nano-
particles’ properties for the selected irradiation mode.
We shall now turn our attention to the second issue 
connected with the problem of targeted delivery of 
nanoparticles into the tumor. This issue has two sig-
nificant aspects: increasing the contrast in the desired 
biotarget and decreasing the side effects conditioned 
by the accumulation of GNP in other organs, primar-
ily in the liver and spleen (see below). Two delivery 
strategies are typically used. The first strategy is based 
on GNP conjugation with PEG, and the second one is 
based on GNP conjugation with antibodies to certain 
marker proteins of tumor cells. PEG is used to enhance 
the bioavailability and stability of nanoparticles, result-
ing in the increase in time of their circulation in blood 
flow. Citrate-coated gold nanospheres and CTAB-coat-
ed nanorods and nanoshells are characterized by low 
stability in buffer saline solutions. Upon conjugation of 
nanoparticles with PEG, their stability increases con-
siderably, preventing salt-induced aggregation.
PEGylated nanoparticles are preferentially accu-
mulated in vivo due to the enhanced permeability of 
tumor vessels [161] and are retained in it due to the re-
duced lymphatic drainage. Moreover, PEGylated na-
noparticles possess lower availability for the immune 
system (stealth technologies). This delivery method is 
called passive delivery, as opposed to the active meth-
od, in which antibodies are used [162] (Fig. 9). The ac-
tive delivery method is more reliable and efficient. 
Antibodies to tumor markers are used in it. Most fre-
quently, the epidermal growth factor receptor (EGFR) 
and its varieties (e.g., Her2) [152, 163], and the tumor 44 | ACTA NATURAE |  VOL. 3  № 2 (9)  2011
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necrosis factor, (TNF) [164] serve as such markers. The 
use of GNP conjugated with antibodies simultaneously 
for diagnostics and photothermal therapy (the so-called 
theranostics methods) seems to be the most promising 
[165]. In addition to antibodies, folic acid, ligand of nu-
merous folate receptors of tumor cells [150], and hor-
mones [166] can be used for active delivery.
The question of the efficacy of targeted delivery of 
nanoparticles into the tumor has recently resurfaced 
as the subject of investigation and discussion [167]. In 
experiments with liposomes labeled with anti-Her2-
antibodies [168] and GNP labeled with transferrine 
[169], it was shown that functionalization improves the 
penetration of nanoparticles into cells; however, the 
contrast of particle accumulation in the tumor does 
not improved considerably. The biodistribution and 
localization of gold nanorods labeled with three types 
of probe molecules, including the (1) scFv-fragment of 
EGFR antibodies; the (2) N-terminal fragment of the 
peptide recognizing the urokinase plasminogen activa-
tor receptor (uPAR); and the (3) cycliс RGD-peptide 
recognizing the αvβ3-integrin receptor have been stud-
ied [167]. It appears that all three types of ligands fail to 
significantly improve the contrast of particle accumu-
lation in cell models and in the tumor upon intravenous 
administration, but they do have a considerable effect 
on extracellular distribution and intracellular localiza-
tion. Therefore, a conclusion can be made that in the 
case of PPTT, the direct introduction of particles into 
the tumor can be more efficient than intravenous ad-
ministration. 
The last important question associated with mod-
ern PPTT has to do with the efficient delivery of ra-
diation to the biotarget. Since the absorption of biotis-
sue chromophores in the visible region is lower by two 
orders of magnitude than it is in the infrared region 
[138], the use of IR radiation dramatically reduces the 
nontarget thermal dose and increases the deep tissue 
penetration of the radiation. Nevertheless, the pene-
tration depth typically does not exceed 5–10 mm [142, 
170]; therefore, it is necessary to search for alternative 
solutions. The first approach consists in using impulse 
(nanoseconds) modes of radiation instead of continu-
ous ones, which allow to increase the intensity of the 
irradiation without additional side effects. The second 
approach consists in using fibre-optic devices for endo-
scopic delivery of the radiation or delivery inside the 
tissue. The advantages and drawbacks of this approach 
are evident. Finally, radiation with deeper penetration, 
such as radio radiation [171], can be used for hyper-
thermia.
GNP conjugated with antibiotics and antibodies 
have also been used as photothermal agents to inflict 
selective damage to protozoa and bacteria [172, 173]. 
The data on some questions related to the use of PPTT 
can be found in books and reviews [139, 170, 174, 175]. 
The thorough review [138] warrants special attention.
2.2. Photodynamic therapy using gold particles
The photodynamic method [176] is applied in the ther-
apy of oncological diseases, certain dermal or infec-
tious diseases, and is based on the use of light-sensitive 
agents – photosensitizers (including dyes) and, typi-
cally, visible light of a certain wavelength. Most fre-
quently, the sensitizers is introduced into the organism 
intravenously; it may also be administered applicative-
ly or perorally. The agents for photodynamic therapy 
(PDT) can selectively accumulate in the tumor or other 
target tissues (cells). The affected tissues are radiat-
ed with laser light with a wavelength corresponding 
to the absorption maximum of the dye. In addition to 
the usual heat release due to absorption [6], the sec-
ond mechanism is also significant. It is associated with 
the photochemical generation of singlet oxygen and 
the formation of highly active radicals inducing necro-
sis and apoptosis of tumor cells. PDT results in tumor 
malnutrition and death due to the damage inflicted on 
its microvessels. The major drawback of PDT is that 
the photosensitizers remain in the organism for a long 
period of time; as a result, the patient’s tissues remain 
highly sensitive to light. On the other hand, the use of 
dyes for the selective heating of tissues [6] is character-
ized by low efficacy due to the small absorption cross-
section of chromophores.
It is well-known [177] that metal nanoparticles are 
efficient fluorescence quenching agents. However, it 
has been recently demonstrated [178] that the fluores-
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Fig. 9. Scheme of the plasmon photothermal therapy with 
an active delivery of GNPs to cancer cells. Reproduced 
from Ref. [8] by permission of Elsevier.REVIEWS
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cence intensity can be amplified by a plasmon particle, 
by locating molecules at optimum distance from the 
metal. Theoretically, this idea can be used to enhance 
the efficacy of PDT.
In a number of studies, the proposed method allowed 
to deliver drugs in polyelectrolyte capsules on GNP 
that disintegrate under laser radiation and deliver the 
therapeutic agent to the targets [179, 180] or to use na-
noparticles surrounded by a layer of polymer nanogel 
[181, 182]. Moreover, photoactive agents [183] and pep-
tides facilitating the intracellular penetration [184] are 
used within conjugates. It has recently been proposed 
[185] to use composite nanoparticles that, in addition to 
gold nanoshells, comprise magnetic particles, photody-
namic dye, PEG, and antibodies. Finally, according to 
the data [186], nanoparticles conjugated with photody-
namic dyes can have a synergetic antimicrobial effect.
Thus, gold nanostructures with plasmon resonance 
show promise for the selective PPTT of oncological and 
other diseases. However, it is clear that a number of 
questions require further study, such as: stability, bio-
compatibility, chemical interaction between nanopar-
ticle conjugates in physiological environments, blood 
circulation time, penetration into the tumor, interac-
tion with the immune system, excretion of nanoparti-
cles, etc. We expect that the success in the initial stages 
in the use of nanoparticles for selective PPTT will be 
broadened to the clinical stage [138], provided that the 
optimal technical parameters are studied further.
2.3. The use of gold nanoparticles as therapeutic agents
Gold nanoparticles are increasingly actively being used 
not only in diagnostics and cell photothermolysis ex-
periments, but also for therapeutic purposes. In 1997, 
the successful application of colloidal gold in a patient 
with rheumatoid arthritis was first reported [187]. In 
2008, a vast array of data on the ten-year-long clini-
cal trials of the preparation Aurasol® for peroral ad-
ministration upon severe forms of rheumatoid arthritis 
was published [188]. The positive results achieved upon 
intra-articular introduction of colloidal gold into rats 
with collagen-induced arthritis were described [189]. 
The authors attribute the positive effect to an increase 
in anti-angiogenic activity due to the binding between 
GNP and the vascular endothelial growth factor and, 
therefore, the decrease in macrophage infiltration and 
inflammation. Similar results were obtained upon sub-
cutaneous introduction of gold nanoparticles into rats 
with collagen- and pristan-induced arthritis [190].
Researchers from Maryland University used a col-
loidal gold vector to deliver the TNF to solid tumors 
in mice [191, 192]. Upon intravenous injection, GNP 
conjugated with TNF rapidly accumulates in tumor 
cells and is not detected in cells of the liver, spleen, and 
other healthy organs. Accumulation of GNP in the tu-
mor is attested by the change in the color of the tumor; 
the tumor acquires a bright red/purple color (the color 
typical of colloidal gold and its aggregates), which co-
incides with the maximum of tumor-specific activity of 
the TNF (Fig. 10). The colloidal gold–TNF vector had 
lower toxicity and a higher efficacy in reducing tumor 
size in comparison with the native TNF, since maxi-
mum antitumor reaction was attained by using lower 
doses of the drug. The preparation for intravenous ad-
ministration based on a GNP–TNF conjugate named 
AurImmune™ has already passed the second stage of 
clinical trials.
The antiangiogenic properties of GNP [193] were 
observed in vitro and in vivo. It turned out that GNP 
interact with heparin-binding glycoproteins – vas-
cular permeability factors, growth factors of cardiac 
endothelium and fibroblasts. These agents mediate 
angiogenesis, including that in tumor tissues; there-
fore, GNPs inhibit their activity. Since intensive angio-
genesis (the process of formation of new blood vessels 
in organs or tissues) is considered as one of the main 
tumor growth factors, the existence of antiangiogenic 
properties in GNPs could make them promising for 
tumor therapy. It was also demonstrated by the same 
researchers that gold nanoparticles enhance the apo-
ptosis of the chronic lymphocytic leukemia cells that 
are stable to programmed death [194] and suppress the 
proliferation of multiple myeloma cells [195].
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Fig. 10. Accumulation of the GNP-TNF conjugates in mice 
tumors over 5 h after injection. A MC-38 tumor-burdened 
C57/BL6 mouse was intravenously injected with 15 µg 
of the GNP-TNF conjugates. The ventral surface of the 
animal was photographed at the indicated times, show-
ing the color changes of the tumor over 5 hr. Red arrows 
show tumor uptake in the conjugates; blue arrows show 
accumulation of the conjugates in the tissues surrounding 
the tumor. Adapted from Ref. [191] by permission of The 
American Association for Cancer Research.46 | ACTA NATURAE |  VOL. 3  № 2 (9)  2011
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3. GOLD NANOPARTICLES AS DRUG CARRIERS
The targeted delivery of drugs is one of the most prom-
ising and actively developing directions in the medici-
nal use of GNPs [196, 197]. Antitumor agents and anti-
biotics are the most popular objects of target delivery.
The options of using GNP conjugated with the fol-
lowing antitumor agents were proposed: paclitaxel 
[192], methotrexate [198], daunorubicine [199], hem-
cytabin [200], 6-mercaptopurine [201], dodecylcysteine 
[202], sulfonamide [203], 5-fluorouracil [204], platinum 
complexes [205], kahalalide [206], tamoxifen [207], her-
ceptin [208], doxorubicin [209], prospidin [210], etc. The 
conjugation was carried out either by simple physical 
adsorption of the drugs onto GNPs or via the use of 
alkanethiol linkers. The effect of conjugates was as-
sessed both (chiefly) on in vitro models, using tumor 
cell cultures, and in vivo, in mice with induced tumors 
of different natures and localizations (Lewis lung car-
cinoma, pancreatic adenocarcinoma, etc.). In addition 
to the active substance, target molecules (e.g., cetuxi-
mab) providing better anchoring and penetration of the 
complex into the target cells were used to design the 
delivery system. It was also proposed to use multimodal 
delivery systems, when a gold nanoparticle is loaded 
with several therapeutic agents (both hydrophilic and 
hydrophobic) and auxiliary agents, such as target mol-
ecules, dyes for photodynamic therapy, etc. [211]. Most 
researchers note high the efficacy of antitumor agents 
conjugated with gold nanoparticles.
Antibiotics and other antibacterial agents are also 
considered as objects that can be delivered by gold na-
noparticles. The possibility of producing a stable com-
plex of vancomycin and colloidal gold and the efficacy 
of such a complex against various enteropathogenic 
strains of Escherichia coli, Enterococcus faecium, En-
terococcus faecalis (including vancomycin-resistant 
strains) have also been demonstrated [212]. Similar re-
sults were obtained in [213]: a complex of ciprofloxacin 
with gold nanoshells showed high antibacterial activ-
ity towards E. coli. The anti-leukemia drug 5-fluoro-
uracil, conjugated with colloidal gold, has a noticeable 
antibacterial and antifungal effect against Micrococcus 
luteus, Staphylococcus aureus, Pseudomonas aerugi-
nosa, E. coli, Aspergillus fumigates, and A. niger [214]. It 
should be noted that in all of the listed cases, the com-
plexes of drugs with gold nanoparticles were stable, 
which could be attested by the optical spectra of con-
jugates.
On the contrary, stable complexes with gold na -
noparticles could not be obtained for such antibiotics 
as ampicillin, streptomycin, kanamycin, hentamycin, 
neomycin, ciprofloxacin, gatifloxacin, and norfloxacin, 
which are active against E. coli, M. luteus, S. aureus, 
and P. aeruginosa [215–217]. Nevertheless, their ac-
tivity when mixed with colloidal gold was higher by 
12–40% than that of the antibiotic when used alone, 
depending on the antibiotic. On the basis of these data, 
the authors arrived at the conclusion that the antibac-
terial activity of antibiotics was enhanced by GNPs. 
However, the issue of the mechanisms underlying the 
possible boosting of the antibacterial effect of drugs has 
remained unsolved. It has been proved experimentally 
[218] that unbound gentamicin and a mixture of it with 
gold nanoparticles do not considerably differ in terms 
of their antimicrobial activity in tests on both dense 
and liquid nutrient media. It is speculated that stable 
conjugates of nanoparticles coated with antibiotic mol-
ecules are required to enhance the antibacterial activ-
ity. Thus, it was proposed to use the antibiotic cefaclor 
directly in the synthesis of GNPs. As a result, a stable 
conjugate was obtained. It was characterized by high 
antibacterial activity against E. coli and S. aureus. 
There has been much less data on other drugs con-
jugated with gold nanoparticles. However, the high 
anti-oxidant activity of the tocoferol complex with gold 
nanoparticles should be noted, along with [220] the var-
iants of its potential use that were proposed. Data has 
been published [22] indicating that, due to high local 
concentration, GNPs conjugated with the drug TAK-
799 manifested a more pronounced activity against the 
human immunodeficiency virus, as compared with the 
drug itself. The procedure of per oral and intranasal 
introduction of insulin conjugated with colloidal gold 
was elaborated on rat models of diabetes mellitus. A 
decrease in blood sugar levels comparable with the ef-
fect of a subcutaneous introduction of insulin was reli-
ably demonstrated [222]. Finally, the therapeutic effect 
of the antirheumatic drug etanercept conjugated with 
gold nanorods has been described [223].
In the end of this section, we would like to men -
tion gene therapy, which seems to be the ideal strat-
egy concerning genetics, as well as acquired, diseases 
[224]. Gene therapy implies an approach based on the 
introduction of genetic structures into cells and the or-
ganism for therapeutic purposes [225]. The desired ef-
fect was achieved either due to the expression of the 
inserted gene or by partial or complete suppression of 
the function of the damaged or overexpressed gene. 
Attempts to adjust the structure and function of the ill-
functioning (affected) gene were recently made. In this 
case, gold nanoparticles can act as an efficient agent for 
delivering the genetic material into the cytoplasm and 
cell nucleus [226].
4. IMMUNOLOGIC PROPERTIES OF 
GOLD NANOPARTICLES 
Since the 1920s, researchers have shown keen inter-REVIEWS
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est in the immunological properties of colloidal metals 
(gold, in particular). This has been associated mainly 
with the physicochemical (non-specific) immunity 
theory proposed by J. Bordet, which postulates that 
immunogenicity and antigenic specificity depend 
predominately on the physicochemical properties of 
the compounds and, first and foremost, on their col-
loidal state. L.A. Zilber was successful in his attempts 
to obtain agglutinating sera from colloidal gold [227]. 
Moreover, it was shown in a number of studies that the 
introduction of a rigorous antigen, together with col-
loidal metals, stimulates the production of antibodies. 
Furthermore, it was found that certain haptenes ad-
sorbed on colloidal particles can cause the formation 
of antibodies. In one of the best early reviews [228], a 
trove of data on the effect of colloidal gold on nonspe-
cific immune reactions was provided [228]. In particu-
lar, it was noted that, 2 h after 5 ml of colloidal gold is 
introduced intravenously into rabbits, the leukocyte 
content in 1 ml of blood considerably increases (from 
9900 to 19800) against a negligible decrease in mono-
nuclear forms (from 5200 to 4900) and a considerable 
increase in polynuclear forms (from 4700 to 14900). It 
should be noted that such effects have not been ob-
served upon the introduction of other colloidal metals. 
Unfortunately, with the development of immunology 
and the negation of many postulates in Bordet’s theory, 
interest towards the immunological properties of col-
loids has abated. However, the data on the amplifica-
tion of the immune response to antigens adsorbed on 
colloidal particles has been used in the design of various 
adjuvants.
It is known that antibody synthesis is induced by 
agents that have an appreciably developed structure 
(immunogenicity). They include proteins, polysaccha-
rides, and certain synthetic polymers. On the contrary, 
a considerable share of biologically active compounds 
(vitamins, hormones, antibiotics, narcotics, etc.) have a 
relatively low molecular weight and, therefore, cause a 
low immune response. In order to overcome this limita-
tion in the standard methods used to produce antibod-
ies in vivo, such agents (haptens) are chemically bound 
to high-molecular-weight carriers (most frequently, to 
proteins), making it possible to produce specific antisera. 
However, such antisera usually contain accompanying 
antibodies to the antigenic structures of the carrier [229].
In 1986, in a pioneering study by Japanese research-
ers [230], information on a successful attempt at pro-
ducing antibodies to glutamic acid using colloidal gold 
particles as a carrier was published. A number of stud-
ies were subsequently published, in which this method 
was applied and developed in order to produce antibod-
ies to the following haptens and rigorous antigens: ami-
no acids, the platelet-activating factor, quinolinic acid, 
biotin, recombinant peptides, lysophosphatide acid, en-
dostatin, peptides of viral capsid of B and C hepatitis, 
influenza, murrain, α-amidated peptides, actin, anti-
biotics, azobenzene, Аβ-peptide, clenbuterol, surface 
Yersinia antigens, transmissible gastroenteritis virus, 
and tuberculin (see review [231] and refs. therein). In 
all of the works listed, hapten was directly conjugated 
with colloidal gold particles and mixed with Freund’s 
complete adjuvant to immunize animals. As a result, 
sera with a high titre were obtained. The sera required 
no further purification to remove ballast antibodies.
In 1993, it was suggested that hapten (gamma-ami-
nobutyric acid) be bound to the carrier protein before 
its conjugation with colloidal gold [232]. The proposition 
was supported in the studies devoted to the produc-
tion of antibodies to a number of peptides, amino acids, 
phenyl-β-D-thioglucoronide, and diminazene (see [231 
and refs. therein). The antibodies obtained through this 
procedure were characterized by both a high specific-
ity to antigens and a higher titre (“extremely high, ac-
cording to [232]”) –from 1 : 250000 to 1 : 1000000, in 
comparison with those produced using a routine meth-
od. The ImmunoSolution company currently offers an-
tibodies to a number of neurotransmitters and amino 
acids. These antibodies are produced according to the 
procedure in [232].
In 1996, the possibility of using colloidal gold parti-
cles in the antiviral vaccine as the carriers of protein 
antigen of the capsid of the tick-borne encephalitis vi-
rus was first demonstrated [233]. Despite the fact that 
the vaccine contained no adjuvants, the experimental 
vaccine had better protective properties as compared 
with its commercial analogues.
A significant number of studies devoted to the use of 
GNP in designing DNA vaccines with gene construc-
tions encoding proteins, to which antibodies had to be 
produced, have been published. In the case of efficient 
gene expression, these proteins serve as antigens for 
the development of the immune response. Colloidal 
gold particles are the most popular examples of nano-
particles–DNA carriers [234]. 
The technology used to produce antibodies against 
various antigens using colloidal gold as a carrier and 
adjuvant was described in [233, 235]. In this case, an-
tigens are adsorbed directly at the surface of gold na-
noparticles without using any binding agents. It was 
ascertained that the immunization of animals with an 
antigen conjugated with colloidal gold (both using Fre-
und’s complete adjuvant and without it) results in the 
obtainment of specific antibodies with a high titre to a 
wide range of antigens without ballast antibodies. Gold 
nanoparticles can stimulate antibody synthesis in rab-
bits, rats, and mice if a lower dose of the antigen is used 
in comparison with the amount that is required when 48 | ACTA NATURAE |  VOL. 3  № 2 (9)  2011
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using a number of conventional adjuvants (Table 2).
Gold nanoparticles used as antigen carriers were 
shown to stimulate the phagocytic activity of mac-
rophages and affect the functioning of lymphocytes, 
which probably is responsible for  their immune-mod-
ulating effect. Moreover, gold nanoparticles and their 
conjugates with low- and high-molecular-weight an-
tigens stimulate the respiratory activity of the cells of 
the reticulo-endothelial system and the activity of the 
mitochondrial enzymes of macrophages [236], which 
may be one of the causal factors behind the adjuvant 
properties of colloidal gold. The fact that gold nanopar-
ticles act both as a carrier and an adjuvant (i.e., rep-
resent haptens to T-cells) should be considered as the 
most interesting side of the manifestation of the im-
mune properties of colloidal gold. In particular, gold 
nanoparticles conjugated with antigens affect T-cell 
activation: a tenfold increase in the proliferation, as 
opposed to that upon the addition of a native antigen, 
was detected. This provides evidence in support of the 
fact that it is fundamentally possible to act directly on 
T-cells with the subsequent activation of macrophages 
and destruction of a pathogen. 
However, none of the studies contains data on the 
mechanisms that underline these properties of gold 
particles. We consider the discussion in [232] on the 
preferable macrophage response to corpuscular an-
tigens, as opposed to the soluble ones, to be undoubt-
edly reasonable. The researchers who study the 
mechanisms of action of DNA vaccines and use gold 
nanoparticles to deliver genetic material into the cell 
also confirm this fact [234]. The role of Kupfer cells 
and Langerhans cells in the formation of the immune 
response was revealed in these studies. The effect 
of dendrite cells on the formation of the immune re-
sponse upon the introduction of an antigen conju -
gated with gold nanoparticles was discussed in [237]. 
Moreover, it was noted that when using nanoparticles 
in medical practice, one should make sure that there 
are no lipopolysaccharides on their surface. The re-
cent studies [238, 239] were devoted to the interac -
tion between the cells of the immune system and gold 
nanoparticles.
The penetration of peptide-conjugated GNP into 
macrophage cytoplasm resulting in their activation was 
shown by electron microscopy [240]. It was ascertained 
that after the conjugates interact with the TLR-4 re-
ceptors of macrophages, the nanoparticles penetrate 
into the cell, which is accompanied by the secretion of 
inflammatory cytokines – TNF, interleukin-1β and in-
terleukin-6–and the inhibition of macrophage prolif-
eration. Upon the introduction of GNP, the amount of 
macrophages decreases, while their size increases [241]. 
The level of interleukin-1 and interleukin-6 and TNF 
also increases. Another (noninflammatory) mechanism 
of penetration of gold nanoparticles into macrophages 
– by interaction with scavenger receptors---is not im-
probable [242]. The effect on nonconjugated colloidal 
gold on immune-competent cells in vivo was studied 
[243]. It was shown that the introduction of GNP into 
mice results in an increase in the proliferation of lym-
phocytes and normal killers and an increase in interleu-
kin-2 production.
We believe that the detection of adjuvant properties 
in GNP creates favorable conditions for the develop-
ment of a new generation of vaccines.
5. BIODISTRIBUTION AND TOXICITY 
OF GOLD NANOPARTICLES
All the facts mentioned above are proof that GNP have 
recently been actively used in different spheres of na-
nomedicine for diagnostic and therapeutic purposes. 
Moreover, they are being introduced parenterally into 
the organism of animals and humans with increasing 
frequency. The acute questions concerning their bio-
distribution, blood stream circulation, pharmacokinet-
ics and removal from the organism, as well as possible 
toxicity at the level of the entire organism or at the 
level of cyto- and genotoxicity, emerged almost at the 
same time when GNP started to be used in medicine. 
It should be noted that data on the biodistribution and 
toxicity of GNP at the time of writing remained scarce 
and inconsistent.
It was demonstrated by the analysis of published 
Table 2. Indices of antibody titres during immunization of rabbits with yersiniose antigen (according to [235])
Preparation First  
immunization
Second  
immunization Reimmunization
Colloidal gold + antigen (1 mg) 1:32 1:256 1:10240
Freund’s complete adjuvant + antigen (100 mg) 1:32 1:256 1:10240
Physiological solution + antigen (100 mg) 1:32 1:256 1:512REVIEWS
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data that the burst in activity regarding investigations 
into the biodistribution and toxicity of GNP took place 
during the past 3–4 years [7, 244–248]. Since numerous 
research groups started their projects independently, 
there is a vast dispersion in the experimental design, 
including the size and shape of particles, functionaliza-
tion methods, types of animals, doses and methods of 
particle introduction, etc. As a result, there has been 
serious discrepancies in the data and conclusions on the 
level and kinetics of biodistribution  for toxicity estima-
tions, as well. Yet, certain tentative conclusions can still 
be made.
Firstly, the organs of the reticuloendothelial system 
serve as the main target for the accumulation of 10–
100 nm GNP; biodistribution homogeneity decreasing 
with decreasing size. The rapid reduction in particle 
concentration in blood and their prolonged retention 
in the organism is associated with the functioning of 
the hepatobiliary system. Since it takes 3 to 4 months 
for the accumulated particles to be excreted from the 
liver and spleen, the question of the doses and possible 
inflammatory processes is of paramount importance.
Secondly, the available data allows for the reasona-
ble assumption that the effect of nanoparticle penetra-
tion via the hematoencephalic barrier depends critical-
ly on their size; 5–20 nm being the upper limit. Thirdly, 
gold nanoparticles 1–2 nm in diameter could be more 
toxic due to the possibility of irreversible binding to 
the biopolymers in cells. Also, numerous experiments 
on cell cultures have revealed no observable toxicity 
in colloidal particles with a size of 3–100 nm, provided 
that the threshold dose does not exceed a value of the 
order of 1012 particles/ml.
Data on in vivo experiments is scarce and somewhat 
inconsistent. It can only be assumed that there is no ob-
servable toxicity upon the short-term (approximately 
one week long) introduction of GNP at a daily dose 
lower than 0.5 mg/kg.
Recent data underscore the interest generated by 
and intensity of studies in the sphere of nanotoxicol-
ogy, whose number has exploded. Figure 11 shows the 
general scheme of a study of the biodistribution and 
toxicity of nanoparticles, which can be used for plan-
ning experiments [248]. For a better insight into the 
problems of the biodistribution and toxicity of GNP, 
we recommend reviews [244–248].
CONCLUSIONS
Thanks to the rapid development in technologies for 
the chemical synthesis of GNP over the past decade, a 
great variety of particles with different sizes, shapes, 
structures, and optical properties are now available to 
contemporary researchers. Moreover, the question of 
the simulation of nanoparticles that would possess the 
desired physical (optical, thermal, etc.) properties, with 
subsequent development of the procedures for synthe-
sizing the simulated structures, is now on the agenda.
In terms of applications in medicine, the develop-
ment of efficient technologies for the functionalization 
of GNP with different classes of molecules providing 
stabilization in vivo and directed interaction with bio-
logical targets is of significance. Today, thiolated deriv-
atives of PEG and other molecules are considered to be 
the best stabilizing agents. In particular, PEG-coated 
particles can remain in the blood flow for a longer time 
and are less susceptible to attacks from the cell compo-
nents of the immune system.
It is now widely accepted that GNP conjugates are 
excellent labels for solving the problems of bioimaging, 
which can be implemented using various optical tech-
nologies, including resonance scattering dark-field mi-
croscopy, confocal laser microscopy, different variants 
of two-photon luminescence of GNP, optical coherence 
tomography, acoustic tomography, etc.
GNP conjugates have found application in analytic 
studies that can be based both on modern instrumen-
tal methods (surface-enhanced Raman spectroscopy, 
LISNA, IR Fourier spectroscopy, etc.) and on the use 
of simple solid-phase or homophase procedures (dot 
analysis, immunochromatography). Two examples can 
be given as illustrations: (1) the prostate-specific an-
tigen can be determined using GNP conjugated with 
antibodies with a sensitivity that is higher than that in 
the conventional immunoenzyme assay by a factor of 
1,000,000 [249]; (2) the strict dependence of color on in-
terparticle distances allows visual detection of mutant 
DNAs in the so-called “Northwestern spot test” [68]. 
Along with the examples of clinical diagnostics of can-
cer, Alzheimer’s disease, HIV, hepatitis, tuberculosis, 
diabetes mellitus, and other diseases, new diagnostic 
applications for GNP should be expected.
Plasmon photothermal laser therapy of cancer using 
GNP was first described in 2003 and recently moved 
into the stage of clinical approval. The actual clinical 
success of this technology will depend on how quickly 
several urgent problems can be solved: (1) developing 
efficient methods for the delivery of radiation to tu-
mors inside the organism using fibre-optic technologies 
or nonoptical heating methods; (2) elaborating methods 
for delivering conjugates to tumors, enhancing the con-
trast and uniformity of accumulation; and (3) develop-
ing methods for controlling the in situ photothermoly-
sis process.
Targeted delivery of DNA, antigens, and drugs us-
ing GNP is one of the most promising directions in bio-
medicine. In particular, the studies performed by Jiang 
et al. of the University of Toronto [250] have revealed 
the size-dependent possibility of herceptin conjugated 50 | ACTA NATURAE |  VOL. 3  № 2 (9)  2011
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GNP into tumor cells with a much higher efficacy in 
comparison with that of the pure preparation. The re-
cent critical revision of the PPTT concept based on the 
intravenous-targeted delivery of GNP conjugated with 
molecular probes to tumor receptors [167] points to the 
necessity to continue studies in this direction. In view 
of the data in [167], it seems quite reasonable to use 
the “non-targeted” PEG-coated gold nanoshells of the 
SiO2/Au type with a nucleus diameter of 120 nm and 
thickness of the gold layer of 15–20 nm as a universal 
marker for PPTT and bioimaging [25, 41]. It should be 
emphasized that N. Halas, J. West, et al. of Rice Uni-
versity (United States) started clinical trials of these 
particles for PPTT in 2010.
Finally, there is a necessity to continue and broaden 
studies of the biodistribution and the toxicity of GNP. 
First of all, a coordinated program is required, which 
would reveal the correlations between particle param-
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Size, shape, structure, charge
TEM, SEM, DLS, UV-vis, EP
Functionalization, opsonization 
of PEG-SH, PEO-SH, BSP TNF-α, 
antibodies, folates
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excretion
RA INAA ICP-MS 
AAS
Аu
Аu
Time
Localization
Identification
Structural 
analysis
HIST
TEM
EDX
XAS
Au
Au Au
0   keV  10
Biological in vitro and in vivo characterization
Recognition and uptake of particles by cells
Cytotoxicity and genotoxicity, apoptosis (MTT, WST-1)
Distribution over organs/metabolism
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Fig. 11. Scheme of biodistribution and nanotoxicology 
experiments. The first step is the fabrication of desired 
particles and the characterization of their size, shape, 
structure, charge by transmission or scanning electron 
microscopy (TEM, SEM), dynamic light scattering (DLS), 
UV-vis spectroscopy at the ensemble (suspension) and 
single-particle levels, electrophoresis, and other methods. 
The second step includes the functionalization of the particle 
surface with appropriate ligands, including thiolated PEG 
or poly(ethylene oxide) (PEO) molecules, tumor necrosis 
factor (TNF-a), antibodies, and folates, as well as opsoni-
zation with blood serum proteins (BSP, like albumin etc.). 
Conjugates are administered to models in accordance with 
the experimental design, i.e., by using selected doses and 
routes of exposure, including intravenous (IV), intraperi-
toneal (IP), respiratory (RE), or gastrointestinal (GA). The 
biodistribution into organs and the kinetics of accumula-
tion/clearance are determined according to a selected 
time-dependent scheme of tissue sampling. Samples are 
analyzed by radioactive analysis (RA), instrumental neutron 
activation analysis (INAA), inductively coupled plasma-mass 
spectrometry (ICP-MS), and atomic absorption spectros-
copy (AAS). Particles and related structures also can be 
identified at the tissue (histological, HIST) and cellular levels 
by electron microscopy (SEM, TEM), energy dispersive 
X-ray spectroscopy (EDX), and X-ray absorption spectros-
copy (XAS). The final step is the integration of data for the 
biological characterization of GNP effects and the evaluation 
of possible risks through the use of cellular-level information 
(cellular recognition and penetration, cytotoxicity, genotox-
icity, and apoptosis/necrosis; MTT and WST-1 assays) and 
at the whole organism level (organ distribution, accumula-
tion and clearance/excretion, degradation and metabolism, 
immunogenicity, and inflammation). Reproduced from Ref. 
[248] (http://dx.doi.org/10.1039/c0cs00018c) by per-
mission from The Royal Society of Chemistry.
eters (size, shape, functionalization with various molec-
ular probes), experimental parameters (model, doses, 
method, and administration scheme, observation dura-
tion; organs, cells, subcellular structures under study, 
etc.), and the observed biological effects. Coordinated 
efforts in the introduction of standards for the particles 
and methods used for the testing of nanomaterial toxic-
ity are also required. 
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